Future Journal of Pharmaceutical Sciences

Table 2 Results of system suitability parameters of 100% level standard solution

From: An effective stability indicating RP-HPLC method for simultaneous estimation of Dolutegravir and Lamivudine in bulk and their tablet dosage form

Injection	Dolutegravir				Lamivudine
Injection	RT	Peak area	USP plate count (N)	USP tailing (T)	RT	Peak area	USP plate count (N)	USP tailing (T)
1	5.065	4,131,307	9923	1.05	3.347	10,699,769	7144	1.05
2	5.068	4,144,851	9943	1.06	3.349	10,691,540	7172	1.06
3	5.068	4,155,263	10,022	1.06	3.348	10,713,746	7120	1.06
4	5.07	4,185,447	10,093	1.06	3.349	10,794,469	7033	1.06
5	5.07	4,180,122	10,079	1.06	3.348	10,783,854	7037	1.05
6	5.07	4,199,707	10,120	1.06	3.349	10,844,344	7079	1.06
Mean	5.068	4,166,116	10,030	1.059	3.348	10,754,620	7097.5	1.06
SD	0.002	26,381.3	81.92	0.004	0.0008	61,889	57.2	0.0048
%RSD	0.039	0.63	0.81	0.39	0.0024	0.58	0.80	0.44

SD standard deviation, %RSD relative standard deviation, RT retention time
Acceptance limit % RSD (≤ 2), USP tailing factor (≤ 2), and USP plate count (> 2000)

Back to article page